L-tryptophan: A rational anti-depressant and a natural hypnotic?

Australian and New Zealand Journal of Psychiatry

Volumn 22, Issue 1, 1988, Pages 83-97

  Boman, Bruce ^a  

^a Repatriation Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; SEROTONIN; TRYPTOPHAN;

AFFECTIVE NEUROSIS; DEPRESSION; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW;

DEPRESSIVE DISORDER; HUMAN; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRYPTOPHAN;

EID: 0023928656     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048678809158946     Document Type: Review

References (184)

1. Wohl MG Goodhart RS. Modern Nutrition in Health and Disease (4th Ed.). Philadelphia: Lea & Febiger, 1968: pp 102–103
2. Coppen A Wood K. Tryptophan and depressive illness: Conflicting biochemical and therapeutic issues. Advances in Biological Psychiatry 1983; 10: 19–29
3. McMenamy RH Oncley JL. The specific binding of L-tryptophan to serum albumin. Journal of Biological Chemistry 1958; 233: 1436–1447
4. Partridge WM. Regulation of amino acid availability to the brain. In: Wurtman R.J., Wurtman J.J.,(eds.) Nutrition and the Brain, Vol I. New York: Raven Press, 1977: 141–204
5. Fernstrom JD Wurtman RJ. Brain serotonin content: Physiological regulation by plasma neutral amino acids. Science 1972; 178: 414–416
6. Hutson PH Knott PJ Curzon G. Control of brain tryptophan concentration in rats on a high fat diet. Nature 1976; 262: 142–143
7. Curzon G Green P Sarna GE, et al. Tryptophan transport mechanisms beyond the blood-brain barrier of the rat. Journal of Physiology (London) 1983; 340: 67–74
8. Tong JH Haufhan S. Tryptophan hydroxylase purification and some properties of the enzyme from rabbit hindbrain. Journal of Biological Chemistry 1975; 250: 4152–4158
9. Gibson CD. Control of monoamine synthesis by amino acid precursors. Advances in Biological Psychiatry 1983; 10: 4–18
10. Swade C Coppen A. Seasonal variations in biochemical factors related to depressive illness. Journal of Affective Disorders 1981; 2: 249–255
11. Eccleston D Ashcroft GW Crawford TBB, et al. Effect of tryptophan administration on 5-HIAA in CSF in man. Journal of Neurology, Neurosurgery and Psychiatry 1970; 33: 269–272
12. Young SN Gauthier S. Effect of tryptophan administration on tryptophan, 5 - hydroxyindoleacetic acid and indoleacetic acid in human lumbar and cisternal cerebrospinal fluid. Journal of Neurology, Neurosurgery and Psychiatry 1981; 44: 323–327
13. Carlsson A Lindqvist M. The effect of L-tryptophan and some psychotropic drugs on the formation of 5 - hydroxytryptophan in the mouse brain in vivo. Journal of Neural Transmission 1972; 33: 23–43
14. Grahame-Smith DG. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. Journal of Neurochemistry 1971; 18: 1053–1066
15. Eccleston D Ashcroft GW Crawford TBB. 5 - HIAA metabolism in rat brain. Journal of Neurochemistry 1965; 12: 493–503
16. Massarotti M Meitto L Savoini E, et al. Effects of brain cortex phospholipids and tryptophan on homovanillic and 5 - hydroxyindoleacetic acid levels on human CSF in relation to age. In: Terry RD, Bolis CL, Toffano G,(eds.) Neural Ageing and its Implications in Human Neurological Pathology, New York: Raven Press, 1982: 135–141
17. Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. IV. Distribution of monoamine nerve terminals in the central nervous system. Acta Physiologica Scandinavica (Suppl 247) 1965; 39–85
18. Williams HL. The new biology of sleep. Journal of Psychiatric Research 1971; 8: 445–478
19. Fuxe K Hokfelt T Ungerstedt U. Morphological and functional aspects of central monoamine neurons. International Review of Neurobiology 1970; 13: 93–126
20. Bhagavan NV. Biochemistry. Philadelphia: Lippincott, 1974: 668–675
21. Wagner DR Weitzman ED. Neuroendocrine secretion and biological rhythms in man. Psychiatric Clinics of North America 1980; 3: 223–250
22. Rosenthal NE Sack DA Carpenter CJ, et al. Antidepressant effects of light on seasonal affective disorder. American Journal of Psychiatry 1985; 142: 163–170
23. Coppen A. Serotonin in the affective disorders. In: Kline N.S.,(Ed.) Factors in Depression. New York: Raven Press, 1974: 33–44
24. Ashcroft GW Crawford TBB Eccleston D, et al. 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological disease. Lancet 1966; 2: 1049–1051
25. Dencker SJ Malm V Roos BF, et al. Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania. Journal of Neurochemistry 1966; 13: 1545–1550
26. Asberg M Thoren P Traskman L, et al. Serotonergic depression: A biochemical subgroup within the affective disorders?. Science 1976; 191: 478–480
27. Bridges PK Bartlett JR Sepping P, et al. Precursors and metabolites of 5-hydroxytryptamine and dopamine in the ventricular cerebrospinal fluid of psychiatric patients. Psychological Medicine 1976; 6: 399–405
28. van Pragg HM Korf J Pute J. 5-Hydoxyindoleacetic acid levels in the cerebrospinal fluid of depressed patients treated with probenecid. Nature 1970; 225: 1259–1262
29. van Pragg HM. Depression and Schizophrenia. A Contribution on their Chemical Pathologies. New York: Spectrum, 1977
30. Sedvall G Fyro B Gullberg B, et al. Relationship in healthy volunteers between concentration of monoamine metabolites in cerebrospinal fluid and family history of psychiatric morbidity. British Journal of Psychiatry 1980; 136: 366–374
31. Cochran E Robins E Grote S. Regional serotonin levels in brain, a comparison of depressed suicides and alcoholic suicides with controls. Biological Psychiatry 1976; 11: 283–294
32. Birkmayer W Riederer P. Biochemical post mortem findings in depressed patients. Journal of Neural Transmission 1975; 37: 95–109
33. Bourne HR Bunney WE Colburn RW, et al. Noradrenaline, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients. Lancet 1968; 2: 805–808
34. Shaw DM Camps FE Eccleston E. 5-Hydroxytryptamine in the hindbrains of depressive suicides. British Journal of Psychiatry 1967; 113: 1407–1419
35. Pare CMB Young DPH Price K, et al. 5-Hydroxytryptamine, noradrenaline and dopamine in brainstem, hypothalamus and caudate nucleus of controls and patients committing suicide by coal gas poisoning. Lancet 1969; 2: 133–135
36. Lloyd KG Farley IJ Deck JHN, et al. Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control subjects. Advances in Biochemical Psychopharmacology 1974; 11: 387–397
37. Korpier Kleinman JE Goodman SI, et al. Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Archives of General Psychiatry 1986; 43: 594–600
38. Roy-Byrne P Post RM Rubinow DR, et al. Cerebrospinal fluid 5-HIAA in suicidal schizophrenic patients. American Journal of Psychiatry 1984; 141: 566–569
39. Roy A Ninnan P Mazonson A, et al. CSF monoamine metabolites in chronic schizophrenic patients who attempted suicide. Psychological Medicine 1985; 15: 335–340
40. Banki CM. Evidence of disturbance of monoamines in depression. Advances in Biological Psychiatry 1983; 10: 176–199
41. Coppen A Eccleston E Peer M. Total and free tryptophan concentration in the plasma of depressive patients. Lancet 1973; 2: 60–63
42. Coppen A Wood K. Tryptophan and depressive illness. Psychological Medicine 1978; 8: 49–57
43. Aylward M. Plasma tryptophan levels and mental depression in post menopausal subjects: Effects of oral piperazine - oestrone sulphate. Int Res Communications System, Medical Science 1973; 1: 30
44. Kishimoto M Hama Y. The level and diurnal rhythm of plasma tryptophan and tyrosine in manic-depressive patients. Yokohama Medical Bulletin 1976; 27: 89–97
45. Fiore CE Malatio LS Petrone G. Differences between plasma tryptophan patterns in endogenous and neurotic depression. Int Res Communications System, Medical Science 1979; 7: 525
46. Banki CM Molnar G Fetete I. Correlations of individual symptoms and other clinical variables with amine metabolites and tryptophan in depression. Archiv fur Psychiatrie und Nervenkrankheiten 1981; 229: 345–353
47. Banki CM Molnar G Vojnik M. CSF amine metabolites, tryptophan and clinical parameters in depression. Journal of Affective Disorders 1981; 3: 81–99
48. Transkman L Asberg M Bertilsson L, et al. Monoamine metabolites in the CSF and suicidal behaviour. Archives of General Psychiatry 1981; 38: 631–637
49. Coppen A Swade C Wood K. Lithium restores abnormal platelet 5-HT transport in patients with affective disorder. British Journal of Psychiatry 1979; 136: 235–238
50. Goodwin FK. Biological basis of drug action in affective disorders. In: Jarvik A.,(Ed.) Psychopharmacology in the Practice of Medicine. New York: Appleton Century Crofts, 1977: 231–240
51. Heninger GR Charney DS Sternberg DE, et al. Serotonergic function in depression. Archives of General Psychiatry 1984; 41: 398–402
52. Banki CM. Evidence of disturbance of monoamines in depression. Advances in Biological Psychiatry 1983; 10: 176–199
53. Quitkin F Rifkin A Klein DF. Monoamine oxidase inhibitors. Archives of General Psychiatry 1979; 35: 749–760
54. Zis AP Goodwin KK. Novel antidepressants and the biogenic amine hypothesis of depression. Archives of General Psychiatry 1979; 36: 1097–1107
55. Grahame-Smith DG Green AR Costain DW. Mechanism of the anti-depressant action of electro-convulsive therapy. Lancet 1978; 1: 254–256
56. Chase TN. Serotonergic function in man. Monographs in the Neural Sciences 1976; 3: 8–14
57. Karobath M Diaz JL Huttunen MO. The effect of L-dopa on the concentrations of tryptophan, tyrosine and serotonin in rat brain. European Journal of Pharmacology 1971; 14: 393–396
58. Coppen A Metcalfe M Carroll JD, et al. Levodopa and L-tryptophan therapy in Parkinsonism. Lancet 1972; 1: 654–658
59. Whitlock A. The psychiatric complications of Parkinson's disease. Australian and New Zealand Journal of Psychiatry 1986; 20: 114–121
60. Shaw JM Lees AJ Stern GM. The impact of treatment with levodopa on Parkinson's disease. Quarterly Journal of Medicine 1980; 49: 283–293
61. Goldstein L Knox WE. Effect of adrenal steroids on tyrosine transaminase and tryptophan pyrrolase activities in the rat liver. Journal of Chronic Diseases 1963; 16: 357–366
62. Curzon G. Relationship between stress and brain serotonin, and their possible significance in affective disorder. Journal of Psychiatric Research 1972; 9: 243–252
63. Curzon G Green AR. Effects of hydrocortisone on rat brain 5-hydroxytryptamine. Life Sciences 1968; 7: 657–660
64. Curzon G. Tryptophan pyrrolase - a biochemical factor in depressive illness?. British Journal of Psychiatry 1969; 115: 1367–1374
65. Curzon G Bridges PK. Tryptophan metabolism in depression. Journal of Neurology, Neurosurgery and Psychiatry 1970; 33: 698–704
66. Green AR Curzon G. The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochemical Pharmacology 1970; 19: 2061–2068
67. Adams PW Rose DP Folkard J, et al. Effect of pyridoxine hydrochloride (vitamin B6) upon depression associated with oral contraception. Lancet 1973; 1: 897–904
68. Beumont PJV. The endocrinology of psychiatry. In: Granville-Grossman K.,(Ed.) Recent Advances in Clinical Psychiatry London: Churchill Livingstone, 1979: 185–225
69. Gibbons EL. Plasma Cortisol in depressive illness. Journal of Psychiatric Research 1962; 1: 162–171
70. Carroll BJ Feinberg M Greden JF, et al. A specific laboratory test for the diagnosis of melancholia. Archives of General Psychiatry 1981; 38: 15–22
71. Rapoport ML Beisel WR. Studies of tryptophan metabolism in experimental animals and man during infectious illness. American Journal of Clinical Nutrition 1971; 24: 807–814
72. de Vita VT Chabner BA Livingstone DM, et al. Anergy and tryptophan metabolism in Hodgkin's disease. American Journal of Clinical Nutrition 1971; 24: 835–840
73. Rose DP Braidman IP. Excretion of tryptophan metabolites as effected by pregnancy, contraceptive steroids and steroid hormones. American Journal of Clinical Nutrition 1971; 24: 673–683
74. Rose DP. Tryptophan metabolism in carcinoma of the breast. Lancet 1967; 1: 239–241
75. Bell EM Mainwaring WIP Bulbrook RD, et al. Relationship between excretion of steroid hormones and tryptophan metabolites in patients with breast cancer. American Journal of Clinical Nutrition 1971; 24: 694–698
76. Barron DN Dent CE Harris H, et al. Hereditary pellagralike skin rash with temporary cerebellar ataxia, constant renal amino-aciduria and other bizarre biochemical features. Lancet 1956; 2: 421–424
77. Moser H., Victor M., Adams R.D., Metabolic and nutritional diseases of the nervous system. In: Wintrobe M.M., Thorn G.W., Adams R.D., et al(eds.) Principles of Internal Medicine. New York: McGraw Hill, 1970: 1803–1817
78. Shaw S Lieber CS. Plasma amino acids in the alcoholic: Nutritional aspects. Alcoholism: Clinical and Experimental Research 1983; 7: 22–27
79. Berglund M. Suicide in alcoholism. A prospective study of 88 suicides. Archives of General Psychiatry 1984; 41: 888–891
80. van Pragg HM. Precursors of serotonin, dopamine and norepinephrine in the treatment of depression. Advances in Biological Psychiatry 1984; 14: 54–68
81. Yuwiler A Brammer GL Morley JE, et al. Short-term and repetitive administration of oral tryptophan in normal men: effects on blood tryptophan, serotonin and kynurenine concentrations. Archives of General Psychiatry 1981; 38: 619–626
82. Goodwin FK Cowdry R Jimmerson D, et al. Serotonin and norepinephrine subgroups in depression. Sci. Proc. American Psychiatric Association 1977; 130: 108
83. Banki CM. Correlation of anxiety and related symptoms with CSF 5-HIAA in depressed women. Journal of Neural Transmission 1977; 41: 135–143
84. Thomson J Rankin H Ashcroft GW, et al. The treatment of depression in general practice: A comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychological Medicine 1982; 12: 741–751
85. Aylward M. The recognition of climateric depression: a theurapeutic role for L-tryptophan. Proceedings of the Second International Meeting on Tryptophan Metabolism. Wisconsin: Madison, 1977
86. Coppen A Shaw DM Herzberg B, et al. Tryptophan in the treatment of depression. Lancet 1967; 2: 1178–1180
87. Broadhurst AD. L-tryptophan verses ECT. Lancet 1970; 1: 1392–1393
88. Coppen A Whybrow PC Noguera R, et al. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Archives of General Psychiatry 1972; 26: 234–241
89. Kline NS Shah BK. Comparable therapeutic efficacy of tryptophan and imipramine. Current Therapeutic Research 1973; 15: 484–487
90. Mac Sweeney DA. Treatment of unipolar depression. Lancet 1975; 2: 510–511
91. Herrington RN Bruce A Johnstone EC, et al. Comparative trial of L-tryptophan and amitriptyline in depressive illness. Psychological Medicine 1976; 6: 673–678
92. Rao B Broadhurst AD. Tryptophan and depression. British Medical Journal 1976; 1: 460
93. Chouinard G Young SN Annable L, et al. Tryptophan - nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatrica Scandinavica 1979; 59: 395–414
94. Lindberg D Ahlfors UG Dencker SJ, et al. Symptom reduction in depression after treatment with L-tryptophan or imipramine. Acta Psychiatrica Scandinavica 1979; 60: 287–294
95. Jensen K Fruensgaard K Ahlfors UG, et al. Tryptophan/imipramine in depression. Lancet 1975; 2: 920
96. Shopsin B. Enhancement of the antidepressant responses to L-tryptophan by a liver pyrrolase inhibitor: a rational treatment approach. Neuropsychobiology 1978; 4: 188–192
97. Moller SE. Tryptophan to competing amino acids ratio in depressive disorder: relation to efficiency of antidepressive treatments. Acta Psychiatrica Scandinavica (Suppl 325) 1985; 72
98. Mollar SF Honore P Larson OB. Tryptophan and tyrosine ratios to neutral amino acids in endogenous depression: relation to anti-depressant response to amitriptyline and lithium and L-tryptophan. Journal of Affective Disorders 1983; 5: 67–79
99. Domino EF Krause PR. Plasma tryptophan tolerance curves in drug free normal controls, schizophrenic patients and prisoner volunteers. Journal of Psychiatric Research 1974; 10: 247–261
100. Harvey NS. Psychiatric disorders in parkinsonism: I. Functional illnesses and personality. Psychosomatics 1986; 27: 91–103
101. Miller EM Nieburg HA. L-tryptophan in the treatment of levodopa induced psychiatric disorders. Diseases of the Nervous System 1974; 35: 20–23
102. Birkmayer W Danielczyk W Neumayer E. Dopaminergic super-sensitivity in parkinsonism. Advances in Neurology 1975; 9: 121–129
103. Lehmann J. Tryptophan malabsorption in levodopa - treated parkinsonian patients: Effects of tryptophan on mental disturbances. Acta Medica Scandinavica 1973; 194: 181–189
104. Fahn S Snider S Prasa ALN, et al. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats. Neurology 1975; 25: 861–865
105. Gehlen W Muller J. Zur therapie der Dopa-Psychosen mit L-tryptophan. Deutsche Medizinische Wochenschrift 1974; 99: 457–463
106. Birkmayer W Neumayer E. Die Behandlung der Dopa-Psychosen mit L-tryptophan. Nervenarzt 1972; 43: 76–78
107. Birkmayer W. Parkinson - Syndrome. Moderne Therapie 1978; 6: 51–59
108. Beasley BL Nutt JD Davenport RW. Treatment with tryptophan of levodopa-associated psychiatric disturbances. Archives of Neurology 1980; 27: 155–156
109. Sweet RD McDowell FH Feigenson JS. Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Neurology 1976; 26: 305–310
110. Prange AJ Wilson IC Lynn CW, et al. L-tryptophan in mania. Archives of General Psychiatry 1974; 30: 56–62
111. Murphy DL Baker M Goodwin FK, et al. L-tryptophan in affective disorders: indoleamine changes and differential clinical effects. Psychopharmacologia 1974; 34: 11–20
112. Mendel SJ Stinnett JL Burns D, et al. Amine precursors and depression. Archives of General Psychiatry 1975; 32: 22–30
113. Farkas T Dunner DL Fieve RR. L-tryptophan in depression. Biological Psychiatry 1976; 2: 295–302
114. Moller SE Kirk L Fremming KH. Plasma amino acids as an index for subgroups in manic depressive psychosis: correlation to effect of tryptophan. Psychopharmacology 1976; 49: 205–213
115. Chouinard G Young SN Annable L, et al. Tryptophannicotinamide combination in the treatment of newly admitted depressed patients. Community Psychopharmacology 1978; 2: 311–318
116. Moller SE Kirk L Honore P. Relationship between plasma ratio of tryptophan to competing amino acids and the response to L-tryptophan treatment on endogenously depressed patients. Journal of Affective Disorders 1980; 2: 47–59
117. Beitman BD Dunner DL. L-tryptophan in the maintenance treatment of bipolar II manic-depressive illness. American Journal of Psychiatry 1982; 139: 1498–1499
118. Walinder J. Combination of tryptophan with MAO inhibitors, tricyclic antidepressants and selective 5-HT reupdate inhibitors. Advances in Biological Psychiatry 1983; 10: 82–93
119. Coppen A Shaw DM Farrell JP. Potentiation of the anti-depressive effect of a monoamine oxidase inhibitor by tryptophan. Lancet 1963; 1: 79–81
120. Glassman AH Platman SR. Potentiation of amonoamine oxidase inhibitor by tryptophan. Journal of Psychiatric Research 1969; 7: 83–88
121. Ayuso-Gutierrez JL Lopez-Ibor Alino JJ. Tryptophan and a MAOI (nialamide) in the treatment of depression. International Pharmacopsychiatry 1971; 6: 92–97
122. Pare CMB. Potentiation of monoamine oxidase inhibitors by tryptophan. Lancet 1963; 2: 527–528
123. van Pragg HM. Indoleamines and the central nervous system. Psychiatrica, Neurologica and Neurochirurgica 1970; 73: 9–36
124. Thomas JM Rubin EH. Case report of a toxic reaction from a combination of tryptophan and phenelzine. American Journal of Psychiatry 1984; 141: 281–283
125. Pope HE Jonas JM Hudson JI, et al. Toxic reactions to the combination of MAOI's and tryptophan. American Journal of Psychiatry 1985; 142: 491–492
126. Lopez-Ibor Albino JJ Guiterriz JLA Inglesias MLM. Tryptophan and amitriptyline in the treatment of depression. International Pharmacopsychiatry 1973; 8: 145–151
127. Walinder J Skott A Nagy A, et al. Potentiation of antidepressant action of clomipramine by tryptophan. Archives of General Psychiatry 1976; 33: 1384–1389
128. Choiunard G Young SN Bradwein J, et al. Tryptophan in the treatment of depression and mania. Advances in Biological Psychiatry 1983; 10: 47–66
129. Walinder J Carlsson A Perrson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. Acta Psychiatrica Scandinavica (Suppl 290) 1981; 63: 179–190
130. Choiunard G Jones BD Young SN, et al. Potentiation of lithium by tryptophan in a case of bipolar illness. American Journal of Psychiatry 1979; 136: 719–720
131. Burns DD Mendels J. Serotonin and affective disorders. In: Essan W.B., Valzelli L.,(eds.) Current Development in Psychopharmacology. New York: Medical and Scientific Books, 1979: 239–359
132. Honore P Moller SE Jorgensen A. Lithium and L-tryptophan compared with amitriptyline in endogenous depression. Journal of Affective Disorders 1982; 4: 79–82
133. Dunner DL Fieve RR. Affective disorder: studies with amine precursors. American Journal of Psychiatry 1975; 132: 180–183
134. Price WA Zimmer B. Effect of L-tryptophan on electro-convulsive therapy seizure time. Journal of Nervous and Mental Disease 1985; 175: 636–638
135. Kirkegaard C Moller SE Bjorum N. Addition of L-tryptophan to electroconvulsive treatment on endogenous depression. Acta Psychiatrica Scandinavica 1978; 58: 457–462
136. D'Elia G Lehman J Raoma R. Evaluation of the combination of tryptophan and ECT in the treatment of depression. Acta Psychiatrica Scandinavica 1977; 56: 303–318
137. Bowers MB. Cerebrospinal fluid 5-hydroxyindoles and behaviour after L-tryptophan and pyridoxine administration to psychiatric patients. Neuropharmacology 1970; 9: 599–604
138. Gayford JJ Parker AL Phillips EM, et al. Whole blood 5-hydroxytryptamine during treatment of endogenous depressive illness. British Journal of Psychiatry 1973; 122: 597–598
139. Dunner DL Goodwin FK. Effect of L-tryptophan on brain serotonin metabolism in depressed patients. Archives of General Psychiatry 1972; 26: 364–366
140. Bunney WE Brodie HKH Murphy DL, et al. Studies of alpha-methyl-paratyrosine, L-dopa, and L-tryptophan on depression and mania. American Journal of Psychiatry 1971; 127: 48–57
141. Copper AJ Datta SR. A placebo controlled evaluation of L-tryptophan in depression in the elderly. Canadian Journal of Psychiatry 1980; 25: 386–390
142. Stern SL Mendels J. Drug combinations in the treatment of refractory depression: a review. Journal of Clinical Psychiatry 1981; 42: 368–373
143. Chambers CA Naylor GJ. A controlled trial of L-tryptophan in mania. British Journal of Psychiatry 1978; 132: 555–559
144. Young SN Sourkes TL. Tryptophan in the central nervous system: regulation and significance. In: Agranoff A.,(ed.) Advances in Neurochemistry. New York: Plenum Press, 1977
145. Shaw DM Macsweeney DA Hewland R, et al. Tricyclic anti-depressants and tryptophan in unipolar depression. Psychological Medicine 1975; 5: 276–278
146. Hartmann E. L-tryptophan: A rational hynotic with clinical potential. American Journal of Psychiatry 1977; 134: 366–370
147. Hartmann E Cravens J List S. Hynotic effects of L-tryptophan. Archives of General Psychiatry 1974; 31: 394–397
148. Jouvet M. Biogenic amines and the states of sleep. Science 1969; 163: 32–41
149. Dahlstrom A Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiologica Scandinavica (Suppl 232) 1964; 62
150. Koella WP Feldstein A Czicman JS. The effect of parachlorophenylalanine on the sleep of cat. Electroencephalography & Clinical Neurophysiology 1968; 25: 481–490
151. Fuxe K Lidbrink P. Biogenic amine aspects of sleep and waking. In: Sleep: Physiology, Biochemistry, Psychology, Pharmacology and Clinical Implications. Basel: Karger, 1973: 12–26
152. Corrodi H Fuxe K Hokfelt T. The effect of some psychoactive drugs on central monoamine neurons. European Journal of Pharmacology 1967; 1: 363–368
153. Wyatt RJ Engelman K Kupper DJ, et al. Effects of L-tryptophan (a natural sedative) on human sleep. Lancet 1970; 2: 842–846
154. Hartmann E Chung R Ching-Piao C. L-tryptophan and sleep. Psychopharmacologica 1971; 19: 114–127
155. Oswald I Ashcroft GW Berger RJ, et al. Some experiments in the chemistry of normal sleep. British Journal of Psychiatry 1966; 112: 391–399
156. Hartmann E Chung R. L-tryptophan: effects on sleep in the normal rat and the rat with lowered brain catecholamines. Psychophysiology 1972; 9: 87–88
157. Hartmann E Chung R. Sleep inducing effects of L-tryptophan. Journal of Pharmacy and Pharmacology 1972; 24: 252–253
158. Makipour H., Iber FL., Hartmann E. Effects of L-tryptophan on sleep in hospitalized insomniac patients. In: Chase M.H., Stem W.C., Walter P.L.,(eds.) Sleep Research, Volume I. Los Angeles: UCLA Brain Information Services, 1972: 65
159. Griffiths WJ Lester BK Coulter JD. Tryptophan and sleep in young adults. Psychophysiology 1972; 9: 345–356
160. Ruther E Davis L Piergies A. Slow wave sleep increase with L-tryptophan and beta adrenergic inhibition in normal volunteers. Paper presented at Third European Congress of Sleep Research. Montpellier: Congress Proceedings,:388–389
161. Gnirss FD Schneider-Helmert D Schenker J. L-tryptophan and oxprenolol: a new approach to the treatment of insomnia. International Pharmacopsychiatry 1978; 11: 180–185
162. Hartmann E. The effect of tryptophan on the sleep dream cycle in man. Psychonomic Science 1967; 8: 479–480
163. Schneider-Helmert D. Interval therapy with L-tryptophan in severe chronic insomniacs. International Pharmacopsychiatry 1981; 16: 162–171
164. Fujii K Watanabe M. Comparative study of tumorigenicity in mice administered transplacentally or neonatally with metabolites of tryptophan and its relatedcompounds. Journal of Cancer Research & Clinical Oncology 1980; 96: 163–168
165. Bryan GT. The role of urinary tryptophan metabolites in the etiology of bladder cancer. American Journal of Clinical Nutrition 1971; 24: 841–847
166. Boyland E Williams DC. The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder. Biochemical Journal 1956; 64: 578–581
167. Yoshida O Brown RR Bryan GT. Relationships between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors. Cancer 1970; 25: 773–780
168. Teulines FAA Peters HA Hop WCJ, et al. A new aspect of the urinary excretion of the tryptophan metabolites in patients with cancer of the bladder. International Journal of Cancer 1978; 21: 140–146
169. Sourkes TL. Toxicology of serotonin precursors. Advances in Biological Psychiatry 1983; 10: 160–175
170. NATIONAL CANCER INSTITUTE. Bioassay of L-tryptophan for possible carcinogenicity DHEW Publication No (NIH) 78–1321. Bethesda: National Institute of Health, 1978
171. Kotake Y Murakami E. A possible diabetogenic role for tryptophan metabolites and effects of xanthurenic acid on insulin. American Journal of Clinical Nutrition 1971; 24: 826–829
172. Murakami E. Studies on the xanthurenic acid - insulin complex. Journal of Biochemistry (Tokyo) 1968; 63: 573–580
173. Fears R Murrell FA. Tryptophan and the control of triglyceride and carbohydrate metabolism in the rat. British Journal of Nutrition 1980; 43: 349–356
174. Price JM Brown RR Rukavina JG, et al. Scleroderma (acrosclerosis). II. Tryptophan metabolism before and during treatment by chelation (EDTA). British Journal of Dermatology 1977; 97: 289–298
175. Stachow A Jablonska S Skiendzielewska A. 5-Hydroxytryptamine and tryptamine pathways in scleroderma. British Journal of Dermatology 1977; 97: 147–154
176. Fries JF Lindren JA Bull JM. Scleroderma like lesions and the carcinoid syndrome. Archives of Internal Medicine 1973; 131: 550–553
177. Carlson JR Yokoyama MT Dickson EO. Induction of pulmonary edema and emphysema in cattle and goats with 3-methylindole. Science 1972; 176: 298–299
178. Atkinson G Bogan JA Breeze RG, et al. Effects of 3-methylindole in cattle. British Journal of Pharmacology 1977; 61: 285–290
179. Ono J Hutson DG Dombro RS, et al. Tryptophan and hepatic coma. Gastroenterology 1978; 74: 196–200
180. Fischer JE Funovics JM Aguirre A, et al. The role of plasma amino acids in hepatic encephalopathy. Surgery 1975; 78: 276–290
181. Goursin DB. Central nervous system hypersensitivity to tryptophan. American Journal of Clinical Nutrition 1971; 24: 821–825
182. ANONYMOUS. Neuroremed (L-tryptophan) in depression and insomnia. Excerpta Medica DHA. New Therapies No 2, 1985
183. Baldessarini RJ. Treatment of depression by altering manoamine metabolism: precursors and metabolic inhibitors. Psychopharmacology Bulletin 1984; 20: 224–239
184. van Pragg HM. Denosologisation of biological psychiatry, or the specificity of 5-HT disturbances in psychiatric disorder. Journal of Affective Disorders 1987; 13: 1–8